Federated Hermes’s Viking Therapeutics VKTX Stock Holding History

Federated Hermes’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,072	Closed	-$664K	–	2242
2025 Q2	$664K	Buy	+25,072	New	+$660K	﹤0.01%	1256
2021 Q2	–	Sell	-468	Closed	-$3K	–	2344
2021 Q1	$3K	Sell	468 -47	-9%	-$331	﹤0.01%	2101
2020 Q4	$3K	Buy	515 +168	+48%	+$1.02K	﹤0.01%	2101
2020 Q3	$2K	Buy	347 +176	+103%	+$1.21K	﹤0.01%	2110
2020 Q2	$1K	Sell	171 -248,966	-100%	-$1.65M	﹤0.01%	2178
2020 Q1	$1.17M	Buy	249,137 +109,356	+78%	+$672K	﹤0.01%	1076
2019 Q4	$1.12M	Buy	139,781 +108,520	+347%	+$791K	﹤0.01%	1237
2019 Q3	$215K	Buy	+31,261	New	+$232K	﹤0.01%	1571

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Federated Hermes's VKTX Position: Q3 2025 in Review

Federated Hermes sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 25,072 shares — an estimated $664K sold.

Federated Hermes first reported a position in VKTX in Q3 2019 and held it in 8 quarters. The position peaked at $1.17M in Q1 2020. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Federated Hermes reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Federated Hermes sold 25,072 Viking Therapeutics shares in Q3 2025, an estimated $664K.
Federated Hermes first reported a position in Viking Therapeutics in Q3 2019 and held it in 8 quarters.
Federated Hermes's Viking Therapeutics position peaked at $1.17M in Q1 2020.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Federated Hermes's 13F filing for Q3 2025, filed 3 Nov 2025.